ARCHIVES

Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Amgen’s Aranesp Sales Dropped By Half, Continue To Fall.

November 14, 2008

Bristol-Myers Survey Predicts Year 2000 Survival of 66%

April 3, 1987

Procedures For Ending IGs Announced

July 10, 1992

NCI Programs: Institute To Contact For Software To Control Ultrasound Imaging

November 19, 1999

In Brief: Sartorelli AACI President, McInTyre President Elect; Moertel to Receive ACCC Clinical Award

July 10, 1987

DeCosse: Colorectal Screening Could Save 6,000 Lives Per Year

November 29, 1991